Valuation: Vectura Group

Market Cap 1B 870M 810M 745M 1.41B 95.83B 1.43B 9.55B 3.74B 47.71B 3.77B 3.69B 158B P/E 2019
-27.3x
P/E 2020 6.2x
Enterprise Value 930M 806M 750M 690M 1.3B 88.73B 1.32B 8.85B 3.47B 44.17B 3.49B 3.42B 146B EV / Sales 2019
2.8x
EV / Sales 2020 3.49x
Free-Float
-
Yield 2019 *
-
Yield 2020 -
25-10-30 Liquidia Technologies, Inc. Enters into an Exclusive Licensing Agreement with Vectura Limited CI
24-09-16 Molex Asia Holdings Ltd. signed an agreement to acquire Vectura Group plc from Vectura Fertin Pharma, Inc. for £300 million. CI
24-04-16 Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate CI
21-12-28 EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation CI
21-12-03 Philip Morris CEO does not need M&A to hit smoke free goals RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
Manager TitleAgeSince
Chief Executive Officer - -
Chief Tech/Sci/R&D Officer - 2016-05-31
Corporate Secretary - 2025-06-29
Director TitleAgeSince
Director/Board Member 53 2023-09-14
Director/Board Member 57 2025-06-29

Financials

2019 2020
Net sales 178M 154M 144M 132M 250M 17.01B 253M 1.7B 664M 8.47B 670M 655M 28.07B 191M 165M 154M 141M 267M 18.18B 271M 1.81B 710M 9.05B 716M 700M 30.01B
Net income -22.1M -19.14M -17.82M -16.39M -30.95M -2.11B -31.38M -210M -82.34M -1.05B -82.99M -81.17M -3.48B 122M 106M 98.69M 90.75M 171M 11.68B 174M 1.16B 456M 5.81B 460M 450M 19.27B
Net Debt -66.5M -57.59M -53.62M -49.3M -93.12M -6.34B -94.43M -632M -248M -3.16B -250M -244M -10.47B -74.4M -64.43M -59.99M -55.16M -104M -7.1B -106M -707M -277M -3.53B -279M -273M -11.71B
Logo Vectura Group
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
Employees
-
Sector
-